Do atypical antipsychotic agents trigger autoimmune diabetes?

Benjamin U. Nwosu, Olga T. Hardy, Amanda Angelescu, Leslie A. Soyka, Mary M. Lee

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Atypical or second-generation antipsychotic agents, such as aripiprazole and olanzapine, are increasingly used in the management of schizophrenia and bipolar disorders in children. The atypical antipsychotic agents have been associated with the development of hyperglycemia, ketoacidosis, and diabetes. The mechanism of atypical antipsychotic-mediated hyperglycemia is unclear. Most of the published reports have been on individuals at risk for type 2 diabetes. We present the first known cases of the development of diabetes and positive glutamic acid decarboxylase antibodies (suggestive of autoimmune diabetes) in adolescents while on treatment with atypical antipsychotics. The nature of their clinical presentations and the time course of antipsychotic therapy to clinical diagnosis of diabetes make us speculate that atypical antipsychotics may shorten the time course of the development of autoimmune diabetes in predisposed children.

Original languageEnglish (US)
Pages (from-to)85-87
Number of pages3
Issue number2
StatePublished - Mar 1 2009


  • Atypical antipsychotics
  • Autoimmune diabetes
  • Diabetic ketoacidosis
  • Hyperglycemia

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Do atypical antipsychotic agents trigger autoimmune diabetes?'. Together they form a unique fingerprint.

Cite this